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Some studies showed that piperine (the alkaloid of piper nigrum) can change the activities of microsomal enzymes.
Midazolam concentration is applied as a probe to determine the CYP3A enzyme activity. This study was done to
determine piperine pretreatment role on midazolam plasma concentration.
Twenty healthy volunteers (14 men and 6 women) received oral dose of piperine (15 mg) or placebo for three days
as pretreatment and midazolam (10 mg) on fourth day of study and the blood samples were taken at 0.5, 2.5 and
5 h after midazolam administration. The midazolam plasma levels were assayed using HPLC method (C18 analytical
column, 75:25 methanol:water as mobile phase, UV detector at 242 nm wavelength and diazepam as internal standard).
Data were fit in a “one-compartment PK model” using P-Pharm 1.5 software and analyzed under statistical tests.
The mean ±SD of the age and body mass index were 24.3 ± 1.83 years (range: 21–28 years) and 23.46± 2.85,
respectively. The duration of sedation in piperine receiving group was greater that the placebo group (188±59 vs.
102±43 min, p<0.0001). Half-life and clearance of midazolam were higher in piperine pretreatment group compared to
placebo [1.88±0.03 vs. 1.71± 0.04 h (p<0.0001) and 33.62 ± 0.4 vs. 37.09 ± 1.07 ml/min (p<0.0001), respectively].
According to the results, piperine can significantly increases half-life and decreases clearance of midazolam compared
to placebo. It is suggested that piperine can demonstrate those effects by inhibition CYP3A4 enzyme activity in liver
microsomal system.
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Some specific substances of food products and additives
can manipulate drugs disposition and fate in body through
mechanisms that make changes their plasma concentra-
tion [1-3]. These changes will exert as inducers or inhibi-
tors of hepatic microsomal enzymes or transporters
[1,3-5]. Black pepper (piper nigrum) has been used widely
throughout the world. It has been shown that pepper can
change metabolism of some drugs in those that take foods
containing high pepper [6]. Piperine is an isolated alkaloid
of black pepper [7] that belongs to capsaicin like family* Correspondence: moghadamnia@yahoo.com
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stated.[8]. Animal studies have previously demonstrated that pip-
erine inhibits several enzymatic pathways involving P450,
as well as phase II metabolism [9,10].
Grilled meat using wood charcoal, smoked meats, foods
containing cruciferous vegetables, and some medicinal
plants can induce several microsomal and transporter en-
zymes and decrease plasma concentration of xenobiotics,
such as cyclosporine A and anti-HIV protease inhibitors
[11]. Other drugs, such as verapamil induces CYP3A4 and
increases transport of p-glycoproteine precursor [11]. On
the other hand, some foods such as grape fruit can in-
crease plasma concentration of felodipine, nitrondipine,
secoanavir and cyclosporine A by inhibiting of CYP3A
[12,13]. It has been suggested that pretreatment piperine
in mice, may result in increasing plasma concentration of
theophylline [9,14]. This similar effect of piperine on
plasma level of theophylline, rifampine, phenytoin andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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has been reported that administration of 1 g of black pep-
per as a single dose, may increase time-concentration area
under the curve (AUC) of phenytoin more than two times
compared to placebo.
CYP3A enzymes are the most important enzymatic
group that involve in drug metabolism. More than 50%
of microsomal enzymes are made up of CYP3A and
about 60% of drugs used in treatment (e.g. calcium
channel blockers, corticosteroids, sex hormones, macro-
lide antibiotics, benzodiazepines and immunosuppres-
sant drug cyclosporine) are metabolized by CYP3A [16].
Plasma concentration of some drugs such as midazolam
and caffeine can serve as a probe of the enzyme activity
[17,18]. Midazolam is a short acting sedative bezodiaze-
pins that is mainly metabolized by CYP3A4 [7]. Deter-
mination of plasma concentration of midazolam can
help to assess the activity level of CYP3A4 [6].
Based on the mentioned effect of piperine and the im-
portant role of CYP3A in drug metabolism, this study
was designed to investigate the effect of three days pre-
treatment of low dose piperine on midazolam plasma
concentration in healthy volunteers.
Materials and methods
This study has been approved by ethics committee of
Babol University of Medical Sciences (Babol, Iran) and re-
corded in IRCT (Iranian registry of clinical trials) data
bank with registration number:IRCT201203129271N1. All
healthy volunteers were given information of the aims of
the study, methods and possible outcomes of the treat-
ment so that they could understand the main objective of
the investigation. All selected participants signed a written
informative consent form and then they were entered into
the study. Although, neither midazolam nor piperine have
serious side effects at lower doses, all participants were
allowed to leave the study at any time of the follow up
when they developed considerable complications.
Type of study
This was a cross-over controlled study on two groups
(n=10) of healthy volunteers. A one-month period was
considered as wash out time between two trials. Based on
previous reports in 100 healthy volunteers of Mazandaran
province (Northern Iran) to find out the CYP3A activity
and recorded moderate activity in this sample size of the
population [17,18], all participants were selected from
Babol, one of the big cities of the province. After providing
adequate information to the subjects, eligible healthy vol-
unteers will be enrolled in the study. Inclusion criteria: be-
ing healthy; age ranging 18 to 35; normal diet; not
receiving microsomal enzyme inhibitor or inducer agents
for at least 7 days before the study; not using black pepper
for at least 7 days before the study. Exclusion criteria: agebeing below 18 and above 35; smocking; pregnancy; meta-
bolic disorders; high pepper diet, receiving enzyme inhibi-
tors or inducers.
Drugs & chemicals
Midazolam (Exir Lorestan, Iran), EDTA (Sigma Chemical
Co. USA), piperine (Merck, Germany), n-hexan, HPLC
grade methanol, isoamyl alcohol and HCl (Merck,
Germany) and deionized water were used. Standard form
of midazolam and diazepam as base (used as internal
standard) were prepared from Dr. Abidi Pharmaceuitical
Company (Tehran, Iran).
Devices
Centrifuge (Clements 2000, Australia) and HPLC [(Knauer,
Germany); column Eurospher 100–5 C18 of silica gel, di-
mension: 250 × 4.6 mm with pre-column, UV detector,
EZchrom Elite software] were used.
Steps
All participants received adequate description about the
setting, treatment schedule and outcome of drug admin-
istration. Then they recorded their personal information
including age, sex, height, weight, general health situ-
ation, and history of drug use, food sensitivity, smoking,
occupation, education and consent to the study in a spe-
cial form.
Drug administration and sampling
Healthy volunteers regardless of gender were randomly
divided into two control and piperine receiving groups
(n=20 per group). The subject received placebo or piper-
ine (1 capsule 15 mg of piperine daily for 3 days before
midazolam) and midazolam (10 mg as an oral single
dose) on fourth day of the study. Total period of the
study is 4 days. Blood samples (maximum 10 ml) were
taken at 0.5, 2.5 and 5 hour after midazolam administra-
tion. After a month as a wash out period, the treatment
program was exchanged between placebo and piperine
groups and all steps were done as same as the previous.
Blood samples preparation
Blood samples were transferred into labeled tubes con-
taining Ca-EDTA and shake gently to mix Ca-EDTA
with blood for preventing of coagulation.The samples
were centrifuged at 3500 ×g for 15 min and supernatant
plasma layer transferred into a blank tube. Until the assay
of midazolam or diazepam concentration, the plasma sam-
ples were kept at −20°C.
HPLC assay
For measurement of the drugs concentration, plasma
samples were removed from the freezer condition and
left in the laboratory to convert from frozen into a liquid
Table 1 Comparison of the mean (±SD) of onset and
duration of sedative effect and frequency of sedation
and amnesia following midazolam administration in






Placebo 11.25 (±4.5) 102 (±43) 16 4
Piperine 11.75 (±4.9) 188 (±59) 20 7
p value NS* 0.0001 NS NS
*NS: non-significant.
Figure 1 Comparison of duration of sedation (min) after
midazolam (10 mg, p.o.) in placebo and piperine pretreatment
(15 mg p.o. in three sequential days before midazolam)
groups. Total data and data by sex are shown for 20 subjects.
Sedation in piperine pretreatment group is greater than placebo
group (*p<0.001, **p<0.01, ***p<0.0001).
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transferred into a capped falcon tube. In the next step,
100 micl of 1 M NaOH and 100 micl isoamyl alcohol
were added. After a gently shaking, 4.5 ml of n-hexan
was added and shake for 1 minute. The final solutions
were centrifuged at 300 ×g for 5 min. After this step,
4.2 ml of supernatant was drawn and transferred into a
plastic tube and 100 miclof 0.05 M HCl was added to
the solution and centrifuged similar as the previous.
Then the supernatant (organic layer) was discarded and
the remaining was directly injected into the HPLC.
HPLC analysis
The separation was carried out at ambient temperature
using a single-column isocratic reverse-phase method.
The mobile phase consisted of 75% methanol and 25%
water. Flow rate was set at 0.8 ml/min. The extracts
were detected by UV detector at 242 nm wavelength.
Twenty micl of the aqueous layer of final extract was
injected into the HPLC using a Hamilton’s syringe. The
injection was repeated 3 times for each sample. Peaks
area and height were considered for midazolam and di-
azepam detection and used for calculation of the drugs
concentration in the final plasma extract.
Standard preparations
A working solution containing 10 micg of midazolam in
1 mL of mobile phase was prepared. Six standard solu-
tions of different concentrations of midazolam (20, 50, 75,
100, 150 and 200 ng/ml) were prepared. Then 20 micl of
25 ng/ml of diazepam solution as internal standard as
added to each standard concentration of midazolam.
Data handling and analysis
Data were analyzed in two steps. The first; personal in-
formation of the participants and data of drugs assay
were handled using Excel software. Calibration curves
were plotted based on peak area and/or height ratio of
midazolam to diazepam.
The slope, intercept and R2coefficient were calculated.
Coefficient variation (CV) for this analysis was 3.8%.
The second; pharmacokinetic (PK) parameters such as
absorption rate constant (Ka), clearance, half-life and
volume of distribution of midazolam in the placebo and
piperine groups were calculated based on assumed one-
compartment kinetics using P-Pharm software.
Based on non-parametric distribution, data of three
concentrations by time were analyzed using Friedman
test. Wilcoxon U-test was used for the results of clear-
ance, volume of distribution and half-life of midazolam
in piperine group compared to placebo. The difference
of the PK parameters between two groups was consid-
ered statistically significant at p<0.05.Results
The age range of the participants was from 21 to 28 year
(24.3±1.83). Six subjects were female and 14 were male
(mean±SD of age: males: 25±1.26, females: 22.66±1.86).
All participants were healthy volunteer and selected
from Mazandaran province. The subjects’ weight ranged
from 49 to 101 kg (68.05±2.85). Their average (±SD)
BMI was 23.46 (±2.85).
Clinical features
All the subjects experienced sedation and mild hypnosis
following midazolam administration. This situation was
transient and they’ve got improvement during next
4 hours after administration of midazolam. In some sub-
jects, severe sedation and dizziness were observed in pla-
cebo and piperine groups (30% and 55%, respectively).
The mean duration of the sedation in piperine receiving
group was greater than placebo (188±59 vs. 102±43 min,
p<0.0001) (Table 1).
Duration of midazolam sedative effect in piperine pre-
treatment group in the females was greater than the
males when compared to placebo (p=0.027 and p<0.001)
(Figure 1). Seven subjects of piperine group showed pre-
dominant amnesia but only 4 subjects were amnesic in
placebo group. One subject of piperine group showed
Figure 2 Peak area ratios (midazolam/diazepam)-concentration
curve of six different concentrations (ng/ml) of midazolam
containing equal diazepam (25 ng/ml) as internal standard.
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during first hours after drug administration. The supine
position was recommended for participants suffering
from severe dizziness and possible hypotension.
Standard curve
Six concentrations (20, 50, 75, 100, 150 and 200 ng/ml) as
standard solution of midazolam were prepared. Equal vol-
ume of diazepam solution (25 ng/ml) as internal standard
was spiked on each concentration of midazolam. Based on
peak area ratios of different concentration of midazolam
on diazepam, the standard curve was obtained (Figure 2).
The linearity (R2) constant and the line equation are
shown in the Figure 2.
The chromatograms of standard midazolam (50 ng/ml)
and diazepam (25 ng/ml) are shown in Figure 3. Diazepam
was used as internal standard.
The comparison of primary data of drug concentra-
tions showed a significant different between placebo andFigure 3 Chromatograms of midazolam standard concentration (50 npiperine pretreatment groups at 2.5 and 5 hours after
midazolam (p=0.015 and p=0.002, respectively). Analysis
of intra-group variation of concentration by time showed
a significant profile (p=0.03). There was no significant
difference in AUC0-5 of placebo compared to piperine
pretreatment group (411.1± 235.4 vs. 495, 9 ± 273, re-
spectively).Pharmacokinetics parameters were estimated
in an assumed one-compartment model using P-Pharm
software. For comparing final estimation, non-parametric
paired Wilcoxon U-test was applied.
All PK parameters except of Vd, in piperine pretreated
subjects has demonstrated a significant difference com-
pared to placebo (p<000.1). Half-life of midazolam in
piperine pretreatment group is considerably greater than
in placebo (Table 2). For this reason, it could be said that
piperine may decrease metabolism of midazolam.
After modeling with input of initial data assumption
(Cl= 40 ml/min, Vd=80 L, Ka=1, F=1), concentration-
time curves were plotted. Individual Bayesian fits of
concentration (ng/ml) of midazolam by time (h) pro-
file placebo and piperine pretreatment are shown in
Figure 4.
The population plasma midazolam concentrations
time curves in placebo (A) and piperine (B) treatment
groups are shown in Figure 4. Based on the figure (A),
one subject showed an out of range concentration at the
time of 2.5 h. It is considered that the maximum con-
centration in placebo group occurred at 1.5 h after
midazolam administration.
Discussion
This investigation showed 3 days piperine pretreatment
can significant increase elimination half-life (t1/2) and
decrease clearance of midazolam when compared to
control. Our results can demonstrate a possible relation
between midazolam concentration and CYP3A activity.g/ml) and diazepam (25 ng/ml).
Table 2 Comparison of pharmacokinetics (PK) data of
midazolam in placebo and piperine pretreatment groups
Group Clearance Volume Kel† T1/2‡
Placebo (n=20)
Mean 37.09 91.44 0.41 1.71*
Min 34.27 87.63 0.390 1.63
Max 38.48 93.03 0.42 1.78
S.D. 1.07 1.54 0.01 0.04
Fold 1.12 1.06 1.1 1.1
C.V. 2.89 1.69 2.62 2.61
Piperine (n=20)
Mean 33.62 91.43 0.37 1.88
Min 32.63 84.45 0.35 1.86
Max 34.02 92.35 0.37 1.96
S.D. 0.4 1.7 0.01 0.03
Fold 1.04 1.09 1.05 1.05
C.V. 1.2 1.86 1.29 1.33
†Elimination rate constant.
‡Half- life.
*p<0.0001 (with piperine group).
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metabolisms. Thirty percent of cytochrome P450 en-
zymes of liver are made of CY3A4 [19]. It has been esti-
mated that CYP3A4 is responsible for 50 percent of the
metabolism of all drugs that being eliminated via hepatic
microsomal enzymatic system [20,21]. In addition to
having an active role in hepatic metabolism of drugs,
CYP3A4 is sufficiently active in the small intestine
[22,23]. CYP3A4 is active in the metabolism of lipophilic
substrates such as fentanyl, alfentanil, oxycodone, and
methadone [24-28]. CYP3A4 inhibitors that have been
well studied include: azole antifungal agents and a number
of the macrolide antibodies [29]. There are clinically im-
portant examples such as midazolam, alprozolam, atorva-
statin, simvastatin, felodipine, nifedipine, and cyclosporineFigure 4 Bayesian predicted (thin line) and observed (symbols) plasm
receiving groups. Note the different scales of concentrations in the figurethat are affected by this system [29]. Among the CYP3A
substrates, midazolam has been introduced as a predom-
inant substrate of CYP3A4 and CYP3A5 [29]. The metab-
olism of intravenous midazolam can reflect to the rate of
hepatic CYP3A activity but when it is administered by
mouth, the metabolism can demonstrate both liver and
enteral origin of CYP3A [22,23]. Any changes in CYP3A
enzymatic pathway, may affect midazolam metabolism.
CYP3A activity can be affected by different factors such as
genetics, nutritional, environmental, and hormonal and
disease conditions. These variations in CYP3A activity may
create some problems in dosing of the drugs those are me-
tabolized by this enzymatic system. These variations may
increase drug interaction episodes and cause side effects to
the patients. More than 50% of drugs that are eliminated
by liver microsomal enzymes are metabolized by CYP3A
system [20,21].
In the present study piperine the main alkaloid of
black pepper [7], could significantly prolong life time of
midazolam in body. This may increase the pharmaco-
logic activity and can induce and prolong sedative-
hypnotic properties of the drug. These effects of piperine
may be the result of inhibition of CYP3A4 activity. Pre-
vious animal studies have demonstrated that piperine in-
hibits several CYP450 mediated pathways [30]. Piperine
is a selective non-competitive inhibitor of CYP3A but
has lower activity on the other microsomal enzymes. It
can inhibit activity UDP-glucuronosyl transferase as well
[31,32]. Pretreatment of piperine in mice induced higher
plasma levels of theophylline, rifampin, phenytoin and
propranolol and Q10-CoA compared to control [33,34].
Such an effect has been reported in a previous clinical
study [15]. It has been reported that a single dose of 1 g
of black pepper can increase the AUC (area under the
curve of plasma concentration-time) of phenytoin [14].
In the present study piperine was given in low dose and
seems that in this dose, it can change important PK pa-
rameters such as clearance and t/12 of midazolam. Ita midazolam concentrations in placebo (A) and piperine (B)
s.
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ation is not assumed and it can increase the half-life of
midazolam via inhibition of its hepatic microsomal elim-
ination. This may increase duration and severity of side
effects of subject drugs (substrate of CYP3A) following
their elevated plasma levels. As we already showed the
midazolam side effects in piperine pretreated subjects
were considerable compared to placebo. The inhibition
or induction of enteral CYP3A4 and p-glycoprotein can
mediate considerable drug interactions. These of inte-
ractions may be due to a considerable variation in drug
action from no effect to toxic effect of drugs [35-38].
The genes of CYP3A4 and p-glycoprotein are expressed
in enterocytes and the bioavailability of many drugs such
as cyclosporine A, midazolam, verapamil, HIV protease
inhibitors and digoxin could be affected by the enzyme
and transporter [11,36,38-40]. Metabolism of midazolam
when prescribed intravenously shows the activity of hep-
atic CYP3A, but when it is prescribed orally, it can show
the activity of both hepatic and intestinal CYP3A [41,42].
After oxidative metabolism, midazolam changes into
one of its main metabolites, hydroxide midazolam, in
liver, and is mediated in an exceptional rout by CYP3A
isoforms [43,44]. Piperine inhibits p-glycoprotein and
CYP3A activity. Since, these proteins become expressed
in enterocytes and hepatocytes; they have an effective
role in first-pass metabolism of subject drugs. Piperine
content of nutritional regimen can change the levels of
p-glycoprotein and CYP3A substrates in blood when
those administered by mouth [45]. However more re-
searches are needed to prove intestinal or hepatic ef-
fects of piperine, especially to justify their mechanism
in the present study. In this investigation duration of
sedation and possible hypnosis action of midazolam in
females was longer than the males. This may be to the
result from higher plasma level of midazolam after pip-
erine pretreatment in female subjects. Perhaps, it is
concluded that sex may be an important factor to
obtaining plasma concentration of midazolam. This
may be due to higher activity of CYP3A4 in female at
normal condition compared to male [46-49]. In a previ-
ous phenotyping study by the authors, similar results by
sex variability on CYP3A activity has been reported
[17]. For this reason more clinical effects are expected
in females if the enzyme becomes inhibited.
Conclusion
Individual PK variations can significantly determine CYP3A
activity in general population. This may predispose pa-
tients to demonstrate unexpected drug manifestations
compared to normal subjects. According to the present
investigation, piperine may inhibit CYP3A4 activity and
increase the level of midazolam as a substrate of the
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